Onconetix (ONCO) Competitors $0.06 0.00 (-0.17%) Closing price 04:00 PM EasternExtended Trading$0.06 0.00 (-4.03%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. GRCE, LSB, JATT, RLYB, ANVS, SNYR, CDIO, CVM, LSTA, and NNVCShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Grace Therapeutics (GRCE), Lakeshore Biopharma (LSB), JATT Acquisition (JATT), Rallybio (RLYB), Annovis Bio (ANVS), Synergy CHC Corp. (Uplisting) (SNYR), Cardio Diagnostics (CDIO), CEL-SCI (CVM), Lisata Therapeutics (LSTA), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Grace Therapeutics Lakeshore Biopharma JATT Acquisition Rallybio Annovis Bio Synergy CHC Corp. (Uplisting) Cardio Diagnostics CEL-SCI Lisata Therapeutics NanoViricides Onconetix (NASDAQ:ONCO) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Does the media refer more to ONCO or GRCE? In the previous week, Onconetix had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for Grace Therapeutics. Onconetix's average media sentiment score of 0.75 beat Grace Therapeutics' score of 0.63 indicating that Onconetix is being referred to more favorably in the media. Company Overall Sentiment Onconetix Positive Grace Therapeutics Positive Is ONCO or GRCE more profitable? Grace Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -2,758.89%. Onconetix's return on equity of 0.00% beat Grace Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Onconetix-2,758.89% N/A -48.09% Grace Therapeutics N/A -20.10%-17.10% Does the MarketBeat Community believe in ONCO or GRCE? Grace Therapeutics received 1 more outperform votes than Onconetix when rated by MarketBeat users. CompanyUnderperformOutperformOnconetixN/AN/AGrace TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Which has more risk and volatility, ONCO or GRCE? Onconetix has a beta of 3.51, suggesting that its share price is 251% more volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Do analysts recommend ONCO or GRCE? Grace Therapeutics has a consensus target price of $12.00, indicating a potential upside of 474.16%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Onconetix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in ONCO or GRCE? 23.9% of Onconetix shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 11.4% of Onconetix shares are held by insiders. Comparatively, 13.5% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, ONCO or GRCE? Grace Therapeutics has lower revenue, but higher earnings than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnconetix$1.87M2.05-$37.41MN/AN/AGrace TherapeuticsN/AN/A-$12.85M-$1.16-1.80 SummaryGrace Therapeutics beats Onconetix on 8 of the 14 factors compared between the two stocks. Remove Ads Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.84M$6.45B$5.29B$7.34BDividend YieldN/A3.24%5.11%4.31%P/E RatioN/A6.8821.7117.76Price / Sales2.05231.35379.1297.68Price / CashN/A65.6738.1534.64Price / Book0.025.916.433.98Net Income-$37.41M$142.72M$3.21B$247.44M7 Day PerformanceN/A7.98%5.23%4.43%1 Month PerformanceN/A-13.91%-9.53%-7.73%1 Year PerformanceN/A-9.98%10.99%1.28% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.9409 of 5 stars$0.06-0.2%N/A-98.8%$3.84M$1.87M0.0012Short Interest ↓Gap DownGRCEGrace Therapeutics1.9494 of 5 stars$1.80-10.0%$12.00+566.7%N/A$18.25MN/A-1.55N/AGap DownLSBLakeshore Biopharma0.6733 of 5 stars$1.95-6.7%N/AN/A$18.15M$672.27M0.00773Upcoming EarningsShort Interest ↑News CoverageGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$1.03-5.1%N/A-63.7%$17.77MN/A0.003High Trading VolumeRLYBRallybio2.421 of 5 stars$0.42-5.6%$9.75+2,194.7%-86.0%$17.68M$636,000.00-0.2740Analyst ForecastGap DownANVSAnnovis Bio1.453 of 5 stars$1.24-5.7%$37.00+2,896.0%-87.5%$17.58MN/A-0.283Gap UpSNYRSynergy CHC Corp. (Uplisting)3.1198 of 5 stars$2.03-11.7%$10.00+392.6%N/A$17.40M$34.83M0.0040Lockup ExpirationNews CoverageGap DownHigh Trading VolumeCDIOCardio Diagnostics2.1301 of 5 stars$0.33+7.1%$2.00+511.2%-63.7%$17.06M$34,890.000.001Short Interest ↑CVMCEL-SCIN/A$0.21-3.5%N/A-83.1%$16.71MN/A-0.4343Analyst ForecastGap UpLSTALisata Therapeutics2.2615 of 5 stars$1.90-4.5%$15.00+689.5%-27.5%$16.38M$1M-0.7630News CoveragePositive NewsNNVCNanoViricidesN/A$1.04-3.7%N/A+18.6%$16.27MN/A-1.4420Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies GRCE Alternatives LSB Alternatives JATT Alternatives RLYB Alternatives ANVS Alternatives SNYR Alternatives CDIO Alternatives CVM Alternatives LSTA Alternatives NNVC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCO Stock Free ONCO Stock Alerts